Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

N-Terminal Amino Acids Determine KLF4 Protein Stability in 2A Peptide-Linked Polycistronic Reprogramming Constructs.

Reinhardt A, Kagawa H, Woltjen K.

Stem Cell Reports. 2020 Mar 10;14(3):520-527. doi: 10.1016/j.stemcr.2020.01.014. Epub 2020 Feb 27.

2.

Genome-wide microhomologies enable precise template-free editing of biologically relevant deletion mutations.

Grajcarek J, Monlong J, Nishinaka-Arai Y, Nakamura M, Nagai M, Matsuo S, Lougheed D, Sakurai H, Saito MK, Bourque G, Woltjen K.

Nat Commun. 2019 Oct 24;10(1):4856. doi: 10.1038/s41467-019-12829-8.

3.

Metalloprotease-Dependent Attenuation of BMP Signaling Restricts Cardiac Neural Crest Cell Fate.

Arai HN, Sato F, Yamamoto T, Woltjen K, Kiyonari H, Yoshimoto Y, Shukunami C, Akiyama H, Kist R, Sehara-Fujisawa A.

Cell Rep. 2019 Oct 15;29(3):603-616.e5. doi: 10.1016/j.celrep.2019.09.019.

4.

Smarcb1 maintains the cellular identity and the chromatin landscapes of mouse embryonic stem cells.

Sakakura M, Ohta S, Yagi M, Tanaka A, Norihide J, Woltjen K, Yamamoto T, Yamada Y.

Biochem Biophys Res Commun. 2019 Nov 19;519(4):705-713. doi: 10.1016/j.bbrc.2019.09.054. Epub 2019 Sep 19.

PMID:
31543342
5.

Cell-type dependent enhancer binding of the EWS/ATF1 fusion gene in clear cell sarcomas.

Komura S, Ito K, Ohta S, Ukai T, Kabata M, Itakura F, Semi K, Matsuda Y, Hashimoto K, Shibata H, Sone M, Jo N, Sekiguchi K, Ohno T, Akiyama H, Shimizu K, Woltjen K, Ozawa M, Toguchida J, Yamamoto T, Yamada Y.

Nat Commun. 2019 Sep 5;10(1):3999. doi: 10.1038/s41467-019-11745-1.

6.

De Novo DNA Methylation at Imprinted Loci during Reprogramming into Naive and Primed Pluripotency.

Yagi M, Kabata M, Ukai T, Ohta S, Tanaka A, Shimada Y, Sugimoto M, Araki K, Okita K, Woltjen K, Hochedlinger K, Yamamoto T, Yamada Y.

Stem Cell Reports. 2019 May 14;12(5):1113-1128. doi: 10.1016/j.stemcr.2019.04.008. Epub 2019 May 2.

7.

OVOL1 Influences the Determination and Expansion of iPSC Reprogramming Intermediates.

Kagawa H, Shimamoto R, Kim SI, Oceguera-Yanez F, Yamamoto T, Schroeder T, Woltjen K.

Stem Cell Reports. 2019 Feb 12;12(2):319-332. doi: 10.1016/j.stemcr.2018.12.008. Epub 2019 Jan 10.

8.

Platforms of in vivo genome editing with inducible Cas9 for advanced cancer modeling.

Jo N, Sogabe Y, Yamada Y, Ukai T, Kagawa H, Mitsunaga K, Woltjen K, Yamada Y.

Cancer Sci. 2019 Mar;110(3):926-938. doi: 10.1111/cas.13924. Epub 2019 Jan 16.

9.

Editorial overview: Embroidering the canvas of life.

Woltjen K, Bortvin A.

Curr Opin Genet Dev. 2018 Oct;52:ii-iv. doi: 10.1016/j.gde.2018.11.002. No abstract available.

PMID:
30470343
10.

In vivo reprogramming drives Kras-induced cancer development.

Shibata H, Komura S, Yamada Y, Sankoda N, Tanaka A, Ukai T, Kabata M, Sakurai S, Kuze B, Woltjen K, Haga H, Ito Y, Kawaguchi Y, Yamamoto T, Yamada Y.

Nat Commun. 2018 May 25;9(1):2081. doi: 10.1038/s41467-018-04449-5.

11.

Srf destabilizes cellular identity by suppressing cell-type-specific gene expression programs.

Ikeda T, Hikichi T, Miura H, Shibata H, Mitsunaga K, Yamada Y, Woltjen K, Miyamoto K, Hiratani I, Yamada Y, Hotta A, Yamamoto T, Okita K, Masui S.

Nat Commun. 2018 Apr 11;9(1):1387. doi: 10.1038/s41467-018-03748-1.

12.

Microhomology-assisted scarless genome editing in human iPSCs.

Kim SI, Matsumoto T, Kagawa H, Nakamura M, Hirohata R, Ueno A, Ohishi M, Sakuma T, Soga T, Yamamoto T, Woltjen K.

Nat Commun. 2018 Mar 5;9(1):939. doi: 10.1038/s41467-018-03044-y.

13.

iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer's Disease.

Kondo T, Imamura K, Funayama M, Tsukita K, Miyake M, Ohta A, Woltjen K, Nakagawa M, Asada T, Arai T, Kawakatsu S, Izumi Y, Kaji R, Iwata N, Inoue H.

Cell Rep. 2017 Nov 21;21(8):2304-2312. doi: 10.1016/j.celrep.2017.10.109.

14.

Evolutionarily Distinctive Transcriptional and Signaling Programs Drive Human Germ Cell Lineage Specification from Pluripotent Stem Cells.

Kojima Y, Sasaki K, Yokobayashi S, Sakai Y, Nakamura T, Yabuta Y, Nakaki F, Nagaoka S, Woltjen K, Hotta A, Yamamoto T, Saitou M.

Cell Stem Cell. 2017 Oct 5;21(4):517-532.e5. doi: 10.1016/j.stem.2017.09.005.

15.

Beta-cell replacement strategies for diabetes.

Kieffer TJ, Woltjen K, Osafune K, Yabe D, Inagaki N.

J Diabetes Investig. 2017 Oct 6. doi: 10.1111/jdi.12758. [Epub ahead of print] Review.

16.

The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis.

Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T, Hotta A, Kondo T, Kitaoka S, Ohta A, Tanaka A, Watanabe D, Morita M, Takuma H, Tamaoka A, Kunath T, Wray S, Furuya H, Era T, Makioka K, Okamoto K, Fujisawa T, Nishitoh H, Homma K, Ichijo H, Julien JP, Obata N, Hosokawa M, Akiyama H, Kaneko S, Ayaki T, Ito H, Kaji R, Takahashi R, Yamanaka S, Inoue H.

Sci Transl Med. 2017 May 24;9(391). pii: eaaf3962. doi: 10.1126/scitranslmed.aaf3962.

17.

Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch.

Hirosawa M, Fujita Y, Parr CJC, Hayashi K, Kashida S, Hotta A, Woltjen K, Saito H.

Nucleic Acids Res. 2017 Jul 27;45(13):e118. doi: 10.1093/nar/gkx309.

18.

Hybrid Cellular Metabolism Coordinated by Zic3 and Esrrb Synergistically Enhances Induction of Naive Pluripotency.

Sone M, Morone N, Nakamura T, Tanaka A, Okita K, Woltjen K, Nakagawa M, Heuser JE, Yamada Y, Yamanaka S, Yamamoto T.

Cell Metab. 2017 May 2;25(5):1103-1117.e6. doi: 10.1016/j.cmet.2017.04.017.

19.

Cellular context-dependent consequences of Apc mutations on gene regulation and cellular behavior.

Hashimoto K, Yamada Y, Semi K, Yagi M, Tanaka A, Itakura F, Aoki H, Kunisada T, Woltjen K, Haga H, Sakai Y, Yamamoto T, Yamada Y.

Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):758-763. doi: 10.1073/pnas.1614197114. Epub 2017 Jan 5.

20.

Report on the Conference on Transposition and Genome Engineering 2015 (TGE 2015): advancing cutting-edge genomics technology in the ancient city of Nara.

Woltjen K, Yamamoto T, Kokubu C, Takeda J.

Genes Cells. 2016 May;21(5):392-5. doi: 10.1111/gtc.12367. Epub 2016 Mar 29.

21.

An EWS-FLI1-Induced Osteosarcoma Model Unveiled a Crucial Role of Impaired Osteogenic Differentiation on Osteosarcoma Development.

Komura S, Semi K, Itakura F, Shibata H, Ohno T, Hotta A, Woltjen K, Yamamoto T, Akiyama H, Yamada Y.

Stem Cell Reports. 2016 Apr 12;6(4):592-606. doi: 10.1016/j.stemcr.2016.02.009. Epub 2016 Mar 17.

22.

Engineering the AAVS1 locus for consistent and scalable transgene expression in human iPSCs and their differentiated derivatives.

Oceguera-Yanez F, Kim SI, Matsumoto T, Tan GW, Xiang L, Hatani T, Kondo T, Ikeya M, Yoshida Y, Inoue H, Woltjen K.

Methods. 2016 May 15;101:43-55. doi: 10.1016/j.ymeth.2015.12.012. Epub 2015 Dec 18.

23.

SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.

Tamaki S, Fukuta M, Sekiguchi K, Jin Y, Nagata S, Hayakawa K, Hineno S, Okamoto T, Watanabe M, Woltjen K, Ikeya M, Kato T Jr, Toguchida J.

PLoS One. 2015 Nov 16;10(11):e0142991. doi: 10.1371/journal.pone.0142991. eCollection 2015.

24.

Reprogramming Roadblocks Are System Dependent.

Chantzoura E, Skylaki S, Menendez S, Kim SI, Johnsson A, Linnarsson S, Woltjen K, Chambers I, Kaji K.

Stem Cell Reports. 2015 Sep 8;5(3):350-64. doi: 10.1016/j.stemcr.2015.07.007. Epub 2015 Aug 13.

25.

Robust In Vitro Induction of Human Germ Cell Fate from Pluripotent Stem Cells.

Sasaki K, Yokobayashi S, Nakamura T, Okamoto I, Yabuta Y, Kurimoto K, Ohta H, Moritoki Y, Iwatani C, Tsuchiya H, Nakamura S, Sekiguchi K, Sakuma T, Yamamoto T, Mori T, Woltjen K, Nakagawa M, Yamamoto T, Takahashi K, Yamanaka S, Saitou M.

Cell Stem Cell. 2015 Aug 6;17(2):178-94. doi: 10.1016/j.stem.2015.06.014. Epub 2015 Jul 16.

26.

Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.

Jin Y, Elalaf H, Watanabe M, Tamaki S, Hineno S, Matsunaga K, Woltjen K, Kobayashi Y, Nagata S, Ikeya M, Kato T Jr, Okamoto T, Matsuda S, Toguchida J.

PLoS One. 2015 Jul 10;10(7):e0131998. doi: 10.1371/journal.pone.0131998. eCollection 2015.

27.

The piggyBac Transposon as a Platform Technology for Somatic Cell Reprogramming Studies in Mouse.

Woltjen K, Kim SI, Nagy A.

Methods Mol Biol. 2016;1357:1-22. doi: 10.1007/7651_2015_274.

PMID:
26126450
28.

Inducible Transgene Expression in Human iPS Cells Using Versatile All-in-One piggyBac Transposons.

Kim SI, Oceguera-Yanez F, Sakurai C, Nakagawa M, Yamanaka S, Woltjen K.

Methods Mol Biol. 2016;1357:111-31. doi: 10.1007/7651_2015_251.

PMID:
26025620
29.

Directed Myogenic Differentiation of Human Induced Pluripotent Stem Cells.

Shoji E, Woltjen K, Sakurai H.

Methods Mol Biol. 2016;1353:89-99. doi: 10.1007/7651_2015_257.

PMID:
25971915
30.

KLF4 N-terminal variance modulates induced reprogramming to pluripotency.

Kim SI, Oceguera-Yanez F, Hirohata R, Linker S, Okita K, Yamada Y, Yamamoto T, Yamanaka S, Woltjen K.

Stem Cell Reports. 2015 Apr 14;4(4):727-43. doi: 10.1016/j.stemcr.2015.02.004. Epub 2015 Mar 12.

31.

Synthetic lateral inhibition governs cell-type bifurcation with robust ratios.

Matsuda M, Koga M, Woltjen K, Nishida E, Ebisuya M.

Nat Commun. 2015 Feb 5;6:6195. doi: 10.1038/ncomms7195.

PMID:
25652697
32.

Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation.

Ohnishi K, Semi K, Yamamoto T, Shimizu M, Tanaka A, Mitsunaga K, Okita K, Osafune K, Arioka Y, Maeda T, Soejima H, Moriwaki H, Yamanaka S, Woltjen K, Yamada Y.

Cell. 2014 Feb 13;156(4):663-77. doi: 10.1016/j.cell.2014.01.005.

33.

Nuclease-mediated genome editing: At the front-line of functional genomics technology.

Sakuma T, Woltjen K.

Dev Growth Differ. 2014 Jan;56(1):2-13. doi: 10.1111/dgd.12111. Epub 2014 Jan 5. Review.

PMID:
24387662
34.

Transient maternal IL-6 mediates long-lasting changes in neural stem cell pools by deregulating an endogenous self-renewal pathway.

Gallagher D, Norman AA, Woodard CL, Yang G, Gauthier-Fisher A, Fujitani M, Vessey JP, Cancino GI, Sachewsky N, Woltjen K, Fatt MP, Morshead CM, Kaplan DR, Miller FD.

Cell Stem Cell. 2013 Nov 7;13(5):564-76. doi: 10.1016/j.stem.2013.10.002.

35.

Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells.

Yamashita A, Liu S, Woltjen K, Thomas B, Meng G, Hotta A, Takahashi K, Ellis J, Yamanaka S, Rancourt DE.

Sci Rep. 2013;3:1978. doi: 10.1038/srep01978.

36.

Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi Myopathy in vitro.

Tanaka A, Woltjen K, Miyake K, Hotta A, Ikeya M, Yamamoto T, Nishino T, Shoji E, Sehara-Fujisawa A, Manabe Y, Fujii N, Hanaoka K, Era T, Yamashita S, Isobe K, Kimura E, Sakurai H.

PLoS One. 2013 Apr 23;8(4):e61540. doi: 10.1371/journal.pone.0061540. Print 2013.

37.

Efficient TALEN construction and evaluation methods for human cell and animal applications.

Sakuma T, Hosoi S, Woltjen K, Suzuki K, Kashiwagi K, Wada H, Ochiai H, Miyamoto T, Kawai N, Sasakura Y, Matsuura S, Okada Y, Kawahara A, Hayashi S, Yamamoto T.

Genes Cells. 2013 Apr;18(4):315-26. doi: 10.1111/gtc.12037. Epub 2013 Feb 6.

38.

Identification of target genes of synovial sarcoma-associated fusion oncoprotein using human pluripotent stem cells.

Hayakawa K, Ikeya M, Fukuta M, Woltjen K, Tamaki S, Takahara N, Kato T Jr, Sato S, Otsuka T, Toguchida J.

Biochem Biophys Res Commun. 2013 Mar 22;432(4):713-9. doi: 10.1016/j.bbrc.2013.01.003. Epub 2013 Jan 10.

PMID:
23313505
39.

Highly efficient site-specific transgenesis in cancer cell lines.

Michael IP, Monetti C, Chiu AC, Zhang P, Baba T, Nishino K, Agha-Mohammadi S, Woltjen K, Sung HK, Nagy A.

Mol Cancer. 2012 Dec 11;11:89. doi: 10.1186/1476-4598-11-89.

40.

An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming.

Gabut M, Samavarchi-Tehrani P, Wang X, Slobodeniuc V, O'Hanlon D, Sung HK, Alvarez M, Talukder S, Pan Q, Mazzoni EO, Nedelec S, Wichterle H, Woltjen K, Hughes TR, Zandstra PW, Nagy A, Wrana JL, Blencowe BJ.

Cell. 2011 Sep 30;147(1):132-46. doi: 10.1016/j.cell.2011.08.023. Epub 2011 Sep 15.

41.

Transgene-free production of pluripotent stem cells using piggyBac transposons.

Woltjen K, Hämäläinen R, Kibschull M, Mileikovsky M, Nagy A.

Methods Mol Biol. 2011;767:87-103. doi: 10.1007/978-1-61779-201-4_7.

PMID:
21822869
42.

Induced pluripotent stem cell lines derived from equine fibroblasts.

Nagy K, Sung HK, Zhang P, Laflamme S, Vincent P, Agha-Mohammadi S, Woltjen K, Monetti C, Michael IP, Smith LC, Nagy A.

Stem Cell Rev Rep. 2011 Sep;7(3):693-702. doi: 10.1007/s12015-011-9239-5. Erratum in: Stem Cell Rev. 2012 Jun;8(2):546.

43.

PhiC31 integrase facilitates genetic approaches combining multiple recombinases.

Monetti C, Nishino K, Biechele S, Zhang P, Baba T, Woltjen K, Nagy A.

Methods. 2011 Apr;53(4):380-5. doi: 10.1016/j.ymeth.2010.12.023. Epub 2010 Dec 23.

PMID:
21185379
44.

Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming.

Samavarchi-Tehrani P, Golipour A, David L, Sung HK, Beyer TA, Datti A, Woltjen K, Nagy A, Wrana JL.

Cell Stem Cell. 2010 Jul 2;7(1):64-77. doi: 10.1016/j.stem.2010.04.015. Epub 2010 Jun 17.

45.

Preview. Inhibition of Tgf-beta signaling improves mouse fibroblast reprogramming.

Woltjen K, Stanford WL.

Cell Stem Cell. 2009 Nov 6;5(5):457-8. doi: 10.1016/j.stem.2009.10.007.

46.

New strategies to generate induced pluripotent stem cells.

O'Malley J, Woltjen K, Kaji K.

Curr Opin Biotechnol. 2009 Oct;20(5):516-21. doi: 10.1016/j.copbio.2009.09.005. Review.

PMID:
19837580
47.

piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells.

Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hämäläinen R, Cowling R, Wang W, Liu P, Gertsenstein M, Kaji K, Sung HK, Nagy A.

Nature. 2009 Apr 9;458(7239):766-70. doi: 10.1038/nature07863. Epub 2009 Mar 1.

48.

Virus-free induction of pluripotency and subsequent excision of reprogramming factors.

Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K.

Nature. 2009 Apr 9;458(7239):771-5. doi: 10.1038/nature07864. Epub 2009 Mar 1.

49.

Orpheus recombination : a comprehensive bacteriophage system for murine targeting vector construction by transplacement.

Woltjen K, Ito K, Tsuzuki T, Rancourt DE.

Methods Mol Biol. 2008;435:79-94. doi: 10.1007/978-1-59745-232-8_6.

PMID:
18370069
50.

Deep screening of recombination proficient bacteriophage libraries.

Thomas B, Woltjen K, Rancourt DE.

Biotechniques. 2003 Jan;34(1):36-8, 40. No abstract available.

Supplemental Content

Loading ...
Support Center